Amgen Announces 2014 First Quarter Dividend

                 Amgen Announces 2014 First Quarter Dividend

PR Newswire

THOUSAND OAKS, Calif., Dec. 13, 2013

THOUSAND OAKS, Calif., Dec. 13, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
announced that its Board of Directors today declared a $0.61 per share
dividend for the first quarter of 2014. The dividend will be paid on March 7,
2014, to all stockholders of record as of the close of business on Feb. 13,

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit and follow us on

Forward-Looking Statements
This news release contains forward-looking statements that involve significant
risks and uncertainties, including those discussed below and others that can
be found in our Form 10-K for the year ended Dec. 31, 2012, and in any
subsequent periodic reports on Form 10-Q and Form 8-K. Amgen is providing
this information as of the date of this news release and does not undertake
any obligation to update any forward-looking statements contained in this
document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. The Company's results may be affected by our
ability to successfully market both new and existing products domestically and
internationally, clinical and regulatory developments (domestic or foreign)
involving current and future products, sales growth of recently launched
products, competition from other products (domestic or foreign), difficulties
or delays in manufacturing our products. In addition, sales of our products
are affected by reimbursement policies imposed by third-party payors,
including governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments and
domestic and international trends toward managed care and healthcare cost
containment as well as U.S. legislation affecting pharmaceutical pricing and
reimbursement. Government and others' regulations and reimbursement policies
may affect the development, usage and pricing of our products. Furthermore,
our research, testing, pricing, marketing and other operations are subject to
extensive regulation by domestic and foreign government regulatory
authorities. We or others could identify safety, side effects or
manufacturing problems with our products after they are on the market. Our
business may be impacted by government investigations, litigation and products
liability claims. If we fail to meet the compliance obligations in the
corporate integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Further, while we routinely obtain
patents for our products and technology, the protection offered by our patents
and patent applications may be challenged, invalidated or circumvented by our
competitors. We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete with
other companies with respect to some of our marketed products as well as for
the discovery and development of new products. Discovery or identification of
new product candidates cannot be guaranteed and movement from concept to
product is uncertain; consequently, there can be no guarantee that any
particular product candidate will be successful and become a commercial
product. Further, some raw materials, medical devices and component parts for
our products are supplied by sole third-party suppliers. Our business
performance could affect or limit our ability to repurchase our common stock
or the ability of the Amgen Inc. Board of Directors to declare a dividend.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)



Press spacebar to pause and continue. Press esc to stop.